CBUS vs RKDA

For growth investors, Arcadia Biosciences, Inc.

(RKDA) is the stronger pick with -3. 7% revenue growth year-over-year, versus -14. 6% for Cibus, Inc. (CBUS). Analysts rate Cibus, Inc. (CBUS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcadia Biosciences, Inc.

(RKDA) delivered a total return of -98. 9%, compared to -99. 3% for Cibus, Inc. (CBUS). Over 10 years, the gap is even starker: CBUS returned -99. 7% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcadia Biosciences, Inc.

(RKDA) is the lower-risk stock at 0. 98β versus Cibus, Inc. 's 3. 12β — meaning CBUS is approximately 217% more volatile than RKDA relative to the S&P 500.

By revenue growth (latest reported year), Arcadia Biosciences, Inc.

(RKDA) is pulling ahead at -3. 7% versus -14. 6% for Cibus, Inc. (CBUS). On earnings-per-share growth, the picture is similar: Cibus, Inc. grew EPS 74. 3% year-over-year, compared to 66. 9% for Arcadia Biosciences, Inc.. Over a 3-year CAGR, CBUS leads at 185. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcadia Biosciences, Inc.

(RKDA) is the more profitable company, earning -48. 1% net margin versus -34. 9% for Cibus, Inc. — meaning it keeps -48. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RKDA leads at -205. 7% versus -1853. 9% for CBUS. At the gross margin level — before operating expenses — RKDA leads at 36. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcadia Biosciences, Inc.

(RKDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Cibus, Inc. (CBUS) carries a higher beta of 3. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RKDA: -99. 9%, CBUS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CBUS (Healthcare) and RKDA (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.